294 related articles for article (PubMed ID: 25083207)
1. Immunogenicity and other problems associated with the use of biopharmaceuticals.
Tovey MG; Lallemand C
Ther Adv Drug Saf; 2011 Jun; 2(3):113-28. PubMed ID: 25083207
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, and Immunogenicity of Interferons.
Tovey MG; Lallemand C
Pharmaceuticals (Basel); 2010 Apr; 3(4):1162-1186. PubMed ID: 27713294
[TBL] [Abstract][Full Text] [Related]
5. Clinical toxicity of cytokines used as haemopoietic growth factors.
Vial T; Descotes J
Drug Saf; 1995 Dec; 13(6):371-406. PubMed ID: 8652081
[TBL] [Abstract][Full Text] [Related]
6. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
Carson KR; Focosi D; Major EO; Petrini M; Richey EA; West DP; Bennett CL
Lancet Oncol; 2009 Aug; 10(8):816-24. PubMed ID: 19647202
[TBL] [Abstract][Full Text] [Related]
9. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
[TBL] [Abstract][Full Text] [Related]
10. Immune-mediated side-effects of cytokines in humans.
Vial T; Descotes J
Toxicology; 1995 Dec; 105(1):31-57. PubMed ID: 8638283
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B.
Martin J; Bosch O; Moraleda G; Bartolome J; Quiroga JA; Carreño V
Hepatology; 1993 Oct; 18(4):775-80. PubMed ID: 8406350
[TBL] [Abstract][Full Text] [Related]
12. [Immunogenicity of biopharmaceuticals: Which consequences during the treatment of rheumatoid arthritis?].
Goupille P
Rev Med Interne; 2016 May; 37(5):343-9. PubMed ID: 26526777
[TBL] [Abstract][Full Text] [Related]
13. Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease.
Lichtenstein GR; Hanauer SB; Sandborn WJ
Gastroenterol Hepatol (N Y); 2012 Nov; 8(11 Suppl 8):1-20. PubMed ID: 24847181
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
[TBL] [Abstract][Full Text] [Related]
15. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
[TBL] [Abstract][Full Text] [Related]
16. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
Sandborn WJ
Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
Bellaguarda E; Keyashian K; Pekow J; Rubin DT; Cohen RD; Sakuraba A
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1919-25. PubMed ID: 26001336
[TBL] [Abstract][Full Text] [Related]
18. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.
Langer-Gould A; Steinman L
Curr Neurol Neurosci Rep; 2006 May; 6(3):253-8. PubMed ID: 16635435
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
[TBL] [Abstract][Full Text] [Related]
20. The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases.
Toussirot É; Bereau M
Inflamm Allergy Drug Targets; 2014; 13(2):121-7. PubMed ID: 24559124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
